DUSSELDORF, Germany, April 29 /PRNewswire-FirstCall/ --
- Strong Focus on the Markets of Pharma & Life Science
- Annual General Meeting Passes Dividend of EUR0.40 per Share
The Annual General Meeting of Gerresheimer AG today passed an unchanged dividend of EUR0.40 per share following the record year in 2008.
The Company finished the financial year 2008 with record results. Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and operating results (adjusted EBITDA) of EUR206.4m (prior year EUR181.6m).
At the Annual General Meeting in Dusseldorf the CEO Dr. Axel Herberg summarized the highlights of the financial year 2008: "We have achieved record levels in terms of sales and earnings. Gerresheimer is on a good course and will show itself to be very robust even in times of crisis."
The shareholders approved the actions of the members of the Company's Supervisory Board and Management Board for the financial year 2008 and, as in the prior year, passed a dividend payment of EUR0.40 per share.
With share capital representation of 59.44% the Annual General Meeting passed the following resolutions:
ITEM 2: Appropriation of net earnings for the financial year 2008:
(99.99% of votes in favor)
ITEM 3: Approval of the actions of the Management Board members for the financial year 2008:
(100% of votes in favor)
ITEM 4: Approval of the actions of the Supervisory Board members for the financial year 2008:
(100% of votes in favor)
ITEM 5: Supplementary election to the Supervisory Board of Mr. Theodor Stuth, Auditor and Certified Tax Advisor, Neuss:
(100% of votes in favor) ITEM 6: Election of the auditor for the financial year 2009: (99.99% of votes in favor) The speech is available onhttp://www.gerresheimer.com/en/press.html. About Gerresheimer
Gerresheimer employs around 10,000 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharmaÂceuÂtical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.(WKN: 587300)
Contact Press Burkhard Lingenberg Director Corporate Communication & Marketing Phone +49-211-6181-250 Fax +49-211-6181-241 e-mail firstname.lastname@example.org Contact Investor Relations Anke Linnartz Director Corporate Investor Relations Phone +49-211-6181-314 Fax +49-211-6181-121 e-mail email@example.com
|SOURCE Gerresheimer AG|
Copyright©2009 PR Newswire.
All rights reserved